
    
      This is a Phase II, randomized, double-blind, placebo controlled, multi-center, comparative
      global study to determine the efficacy and safety of durvalumab + olaparib combination
      therapy versus durvalumab + placebo (durvalumab monotherapy) as first-line treatment in
      patients ineligible for platinum-based chemotherapy with unresectable Stage IV urothelial
      cancer (UC).
    
  